AAREYDRUGS

Aarey Drugs & Pharmaceuticals Share Price

₹53.27 -2.57 (-4.6%)

21 May, 2025 20:03

SIP TrendupStart SIP in AAREYDRUGS

Start SIP

Performance

  • Low
  • ₹53
  • High
  • ₹58
  • 52 Week Low
  • ₹31
  • 52 Week High
  • ₹75
  • Open Price₹58
  • Previous Close₹56
  • Volume101,711

Investment Returns

  • Over 1 Month -4.98%
  • Over 3 Month + 25.43%
  • Over 6 Month -2.31%
  • Over 1 Year + 4.45%
SIP Lightning

Smart Investing Starts Here Start SIP with Aarey Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Aarey Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 26.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 151
  • P/B Ratio
  • 1.1
  • Average True Range
  • 3.22
  • EPS
  • 2.01
  • Dividend Yield
  • 0
  • MACD Signal
  • 2
  • RSI
  • 53.12
  • MFI
  • 55.28

Aarey Drugs & Pharmaceuticals Financials

Aarey Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹53.27
-2.57 (-4.6%)
pointer
  • stock-down_img
  • Bearish Moving Average 9
  • stock-up_img
  • Bullish Moving Average 7
  • 20 Day
  • ₹53.34
  • 50 Day
  • ₹50.30
  • 100 Day
  • ₹50.08
  • 200 Day
  • ₹51.19

Resistance and Support

54.71 Pivot Speed
  • R3 61.14
  • R2 59.48
  • R1 56.37
  • S1 51.60
  • S2 49.94
  • S3 46.83

What's your outlook on Aarey Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarey Drugs & Pharms. has an operating revenue of Rs. 576.20 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 1% needs improvement, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 21% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 93 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarey Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results
2024-12-04 To consider Fund Raising
2024-11-29 Preferential issue of shares Inter alia: a) To consider a proposal for issuance of equity shares by way of a preferential allotment.
2024-11-14 Quarterly Results
2024-10-01 Others

Aarey Drugs & Pharmaceuticals F&O

Aarey Drugs & Pharmaceuticals Shareholding Pattern

44.8%
2.34%
45.79%
7.07%

About Aarey Drugs & Pharmaceuticals

  • NSE Symbol
  • AAREYDRUGS
  • BSE Symbol
  • 524412
  • Chairman & Managing Director
  • Mr. Mihir R Ghatalia
  • ISIN
  • INE198H01019

Similar Stocks to Aarey Drugs & Pharmaceuticals

Aarey Drugs & Pharmaceuticals FAQs

Aarey Drugs & Pharmaceuticals share price is ₹53 As on 21 May, 2025 | 19:49

The Market Cap of Aarey Drugs & Pharmaceuticals is ₹151 Cr As on 21 May, 2025 | 19:49

The P/E ratio of Aarey Drugs & Pharmaceuticals is 26.5 As on 21 May, 2025 | 19:49

The PB ratio of Aarey Drugs & Pharmaceuticals is 1.1 As on 21 May, 2025 | 19:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23